Want to see AU:IXC full AI Analyst Report?
IXC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.18
Previous CloseN/A
Volume14.00K
Average Volume (3M)49.57K
Market Cap
AU$7.52M
Enterprise ValueAU$5.17M
Total Cash (Recent Filing)AU$4.60M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding75,153,850
10 Day Avg. Volume15,093
30 Day Avg. Volume49,574
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.28
Price to Sales (P/S)29.41
P/FCF Ratio-10.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt reduces insolvency risk and preserves strategic flexibility for clinical-stage spending. A meaningful equity base helps absorb ongoing losses and supports continued R&D and regulatory activity over the next several months, lowering immediate refinancing pressure.
Focused Clinical PipelineA concentrated development program (Presendin for IIH) focuses management, conserves R&D resources and clarifies regulatory pathways. This specialization can accelerate decision-making and partnerability, improving long-term odds of a clear clinical/regulatory outcome if trial progress continues.
Improving Loss/cash Outflow TrendYear-over-year narrowing of losses and smaller cash outflows indicates management has begun to moderate burn and improve operational efficiency. If sustained, this trend extends runway and reduces near-term financing needs, supporting continuity of clinical programs over months.
Bears Say
Sharp Revenue DeclineAn 81% revenue decline signals weak commercial traction or lumpy milestone receipts, undermining the prospect of self-funding development. Small, unstable revenue makes the business reliant on external capital or partnerships, raising execution and financing risk over the medium term.
Persistent Negative Operating Cash FlowChronic negative operating and free cash flow requires recurring financing, which can dilute shareholders and consume management time. Without durable positive cash generation or material external funding, sustained burn threatens program continuity and strategic optionality within months.
Ongoing Operating And Net LossesRepeated operating and net losses have produced negative returns on equity and eroded equity levels. Continued unprofitability increases the likelihood of dilution or constrained investment in trials, making successful clinical outcomes or financing essential for longer-term viability.
Invex Therapeutics Ltd. News
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.07 and its highest was AU$0.18 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$7.52M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 24 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Feb 12, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.72%
12-Months-Change
Fundamentals
Return on Equity
-17.07%
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Technical Analysis
Acrux
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Argenica Therapeutics Ltd
―
Botanix Pharmaceuticals Limited
―